found that LAP indeed can inhibit inflammation and liver fibrosis, as both pharmacological and gene-level interventions to inhibit LAP can aggravate inflammatory and fibrotic phenotypes (113). This evidence concerns the gene TGFB1 and Hepatic fibrosis.